Leerink Partnrs Has Bullish Estimate for MOLN Q3 Earnings

Key Points

• Leerink Partners has raised its earnings per share (EPS) estimate for Molecular Partners for Q3 2025 from ($0.53) to ($0.46), indicating improved expectations for the company’s performance.
• Molecular Partners reported a loss of $0.67 EPS in its latest earnings, missing the consensus estimate of ($0.53) by $0.14.
• Institutional investor BVF Inc. IL increased its stake in Molecular Partners by 205.5%, acquiring an additional 910,747 shares, highlighting significant investor confidence in the company.

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for Molecular Partners in a research note issued on Monday, August 25th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($0.46) per share for the quarter, up from their prior estimate of ($0.53). The consensus estimate for Molecular Partners' current full-year earnings is ($1.93) per share. Leerink Partnrs also issued estimates for Molecular Partners' Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.04) EPS and FY2026 earnings at ($1.60) EPS.

Molecular Partners Trading Up 3.7%

Shares of MOLN traded up $0.14 during trading hours on Thursday, hitting $3.89. 538 shares of the stock traded hands, compared to its average volume of 6,496. Molecular Partners has a 1-year low of $3.36 and a 1-year high of $7.60. The firm has a market capitalization of $157.08 million, a PE ratio of -1.87 and a beta of 1.10. The business has a fifty day moving average of $3.70 and a 200-day moving average of $3.95.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last posted its quarterly earnings data on Monday, August 25th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.14).

Institutional Investors Weigh In On Molecular Partners

A hedge fund recently raised its stake in Molecular Partners stock. Suvretta Capital Management LLC boosted its stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) by 455.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,221,494 shares of the company's stock after purchasing an additional 1,821,494 shares during the period. Suvretta Capital Management LLC owned 5.50% of Molecular Partners worth $10,548,000 as of its most recent filing with the SEC. 26.55% of the stock is owned by institutional investors and hedge funds.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.